D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 86 Citations 30,938 585 World Ranking 7430 National Ranking 214

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Chemotherapy

His primary areas of study are Lung cancer, Internal medicine, Oncology, Cancer research and Cancer. His study of Crizotinib is a part of Lung cancer. His Internal medicine study frequently draws parallels with other fields, such as Surgery.

His Oncology research is multidisciplinary, incorporating elements of Survival rate, Gene rearrangement, Clinical trial and Disease. His studies in Cancer research integrate themes in fields like Cancer cell, Mutation, Blockade and Immune system, Immunology. The various areas that Benjamin Besse examines in his Cancer study include Nursing and Pandemic.

His most cited work include:

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (2444 citations)
  • Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer (845 citations)
  • Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial (541 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Oncology, Lung cancer, Cancer research and non-small cell lung cancer. When carried out as part of a general Internal medicine research project, his work on Chemotherapy, Cancer and Phases of clinical research is frequently linked to work in In patient, therefore connecting diverse disciplines of study. His Oncology research integrates issues from Carcinoma, Clinical trial, Lung and Immunotherapy.

His Lung cancer research is multidisciplinary, incorporating perspectives in KRAS and Adenocarcinoma. He has researched Cancer research in several fields, including Liquid biopsy, ROS1, Tyrosine kinase and Immune checkpoint inhibitors. His ROS1 research is mostly focused on the topic Lorlatinib.

He most often published in these fields:

  • Internal medicine (71.41%)
  • Oncology (60.52%)
  • Lung cancer (49.13%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (71.41%)
  • Oncology (60.52%)
  • Cancer research (27.10%)

In recent papers he was focusing on the following fields of study:

His main research concerns Internal medicine, Oncology, Cancer research, Lung cancer and In patient. Chemotherapy, Cancer, Cohort, Immunotherapy and Adverse effect are the core of his Internal medicine study. His Oncology research is multidisciplinary, incorporating elements of Immune system, Lung, Immune checkpoint inhibitors and Second line.

The Cancer research study combines topics in areas such as non-small cell lung cancer, Liquid biopsy, KRAS, ROS1 and Osimertinib. Benjamin Besse has included themes like T790M and Biopsy in his ROS1 study. Benjamin Besse works mostly in the field of Lung cancer, limiting it down to topics relating to Retrospective cohort study and, in certain cases, Bone metastasis, as a part of the same area of interest.

Between 2019 and 2021, his most popular works were:

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials (196 citations)
  • Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. (182 citations)
  • Caring for patients with cancer in the COVID-19 era. (135 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Cancer research and In patient. His study in Adverse effect, Cohort, Cancer, Disease and Clinical endpoint falls within the category of Internal medicine. Particularly relevant to ROS1 is his body of work in Oncology.

His biological study spans a wide range of topics, including Retrospective cohort study, Carcinoma, CD8 and Chemotherapy. His Chemotherapy study combines topics in areas such as PD-L1 and Hazard ratio. He interconnects Epithelial–mesenchymal transition, Kinase, Proto-oncogene tyrosine-protein kinase Src, MAPK/ERK pathway and ALK inhibitor in the investigation of issues within Cancer research.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto.
The New England Journal of Medicine (2013)

3379 Citations

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George.
Nature Genetics (2012)

1064 Citations

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Fabrice Barlesi;Julien Mazieres;Jean-Philippe Merlio;Didier Debieuvre.
The Lancet (2016)

600 Citations

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard;Egbert F Smit;Harry J M Groen;Julien Mazieres.
Lancet Oncology (2016)

556 Citations

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

Julien Mazières;Solange Peters;Benoit Lepage;Alexis B. Cortot.
Journal of Clinical Oncology (2013)

530 Citations

A genomics-based classification of human lung tumors

Danila Seidel;Thomas Zander;Lukas C. Heukamp;Martin Peifer.
Science Translational Medicine (2013)

517 Citations

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor:Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer

Lecia V. Sequist;Benjamin Besse;Thomas J. Lynch;Vincent A. Miller.
Journal of Clinical Oncology (2010)

443 Citations

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Kathryn C. Arbour;Laura Mezquita;Niamh Long;Hira Rizvi.
Journal of Clinical Oncology (2018)

419 Citations

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Alice T Shaw;Enriqueta Felip;Todd M Bauer;Benjamin Besse;Benjamin Besse.
Lancet Oncology (2017)

374 Citations

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Benjamin Besse;Mélinda Charrier;Valérie Lapierre;Eric Dansin.
OncoImmunology (2016)

369 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Benjamin Besse

Alice T. Shaw

Alice T. Shaw

Harvard University

Publications: 100

Guido Kroemer

Guido Kroemer

Sorbonne University

Publications: 84

Fabrice Barlesi

Fabrice Barlesi

Aix-Marseille University

Publications: 79

Alexander Drilon

Alexander Drilon

Memorial Sloan Kettering Cancer Center

Publications: 77

Yi-Long Wu

Yi-Long Wu

Guangdong Provincial People’s Hospital

Publications: 76

Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou

University of California, Irvine

Publications: 75

Jacques Cadranel

Jacques Cadranel

Université Paris Cité

Publications: 74

Gregory J. Riely

Gregory J. Riely

Memorial Sloan Kettering Cancer Center

Publications: 73

Rafael Rosell

Rafael Rosell

Autonomous University of Barcelona

Publications: 71

Pasi A. Jänne

Pasi A. Jänne

Harvard University

Publications: 71

Silvia Novello

Silvia Novello

University of Turin

Publications: 69

Myung-Ju Ahn

Myung-Ju Ahn

Samsung Medical Center

Publications: 69

Mark G. Kris

Mark G. Kris

Memorial Sloan Kettering Cancer Center

Publications: 69

Lorenzo Galluzzi

Lorenzo Galluzzi

Cornell University

Publications: 68

Enriqueta Felip

Enriqueta Felip

Vall d'Hebron Institut de Recerca

Publications: 67

Benjamin Solomon

Benjamin Solomon

Peter MacCallum Cancer Centre

Publications: 65

Something went wrong. Please try again later.